Caplin Point Announces Strong Q1 FY27 Results, Reappoints MD and Approves Final Dividend

Caplin Point Announces Strong Q1 FY27 Results, Reappoints MD and Approves Final Dividend​

Caplin Point Laboratories Limited has released its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also announced significant governance decisions, including the re-appointment of its Managing Director and the recommendation of a final dividend.

The Board of Directors held a meeting on August 12, 2026, where it approved the financial results for the quarter ending June 30, 2026, alongside several key corporate actions regarding management structure and shareholder returns.

Financial Performance Highlights​

The consolidated results show robust growth in revenue and profitability during Q1 FY27 compared to previous periods. Total income stood at 643.91 Crores for the quarter ending June 30, 2026.

Key financial details from the unaudited standalone results for the quarter ended June 30, 2026 are presented below:


The company also reported consolidated figures, reflecting diversified international operations:

Corporate Governance and Management Appointments​

The Board meeting confirmed several strategic appointments and corporate actions:

• Managing Director Re-appointment: Dr. Sridhar Ganesan was re-appointed as the Managing Director of the Company for a further period of two years, effective from August 25, 2026, until August 24, 2028.
• Whole-Time Director Appointment: Mr. D. Muralidharan was appointed as the Whole-Time Director of the Company for a period of two years, effective from August 12, 2026, to August 11, 2028. Mr. D. Muralidharan will continue serving as the Chief Financial Officer (CFO) in addition to his new role.
• Annual General Meeting: The company approved convening its 35th Annual General Meeting on Friday, September 25, 2026, which will be conducted through Video Conferencing / Other Audio-Visual means.

Dividend Recommendation and Shareholder Benefits​

The Board of Directors recommended a Final Dividend of Rs. 4/- (200%) per equity share for the financial year ended March 31, 2026. If approved at the upcoming Annual General Meeting, this dividend is scheduled to be paid on or before October 24, 2026.

Business and Strategic Updates​

Caplin Point Laboratories demonstrated steady growth in both its emerging markets and regulated US markets.

In Emerging Markets, the company secured emergency tenders across Central America amounting to $7 million, set for supply over the next two quarters. In Chile, the company won tenders totaling $12 million, scheduled for delivery over the next 18 months. Furthermore, Caplin has received four additional product approvals in Mexico and maintains a pipeline of over 120 products planned for filing within the next 18 months.

In US and Regulated Markets, Caplin Steriles Limited (CSL) is reported to be growing robustly, with revenues split at 70% from B2B and 30% from B2C. The company has achieved total automation in Quality Control and Microbiology areas at its site and plans to file its first Pre-Filled Syringe (PFS) product within FY27, with a pipeline of over 14 PFS products for filing in FY28.

The company also affirmed an enhanced Capex budget of approximately ₹1000+ Crores for various investment projects, which are intended to augment existing capacities and achieve backward integration across its operations.

CAPLIPOINT Stock Price Movement​

As of 2:42 PM, shares of Caplin Point Laboratories Limited shed 4.86% in live trading, currently registering at ₹2501.9. The decline occurs amid heavy trading volume, with the stock having previously touched its 52-week high despite the current movement.